DRG 311 Overview

DRG 311 covers hospital admissions primarily for angina pectoris, including unstable and rest angina presentations that require inpatient evaluation and management. This Diagnosis-Related Group groups cases by clinical severity and resource use related to ischemic chest pain without major procedures. It matters for Medicare inpatient payment because the assigned Diagnosis-Related Group determines the prospective bundled payment amount based on diagnosis, comorbidities, and length of stay. Accurate coding and documentation of angina and any Complication or Comorbidity or Major Complication or Comorbidity affect reimbursement and case classification.

• Trials of short-term pharmacologic strategies to relieve acute ischemic chest pain in hospitalized patients: these studies evaluate the safety and efficacy of different antianginal medication regimens, routes (e.g., intravenous versus sublingual), and timing of administration for patients admitted with unstable angina or acute exacerbations of chronic angina. The patient population typically includes adults presenting with chest pain without myocardial infarction but at risk for progression, and the research question addresses rapid symptom control and prevention of in-hospital adverse events. Results inform inpatient protocols, length of stay, and resource utilization, which are directly relevant to clinicians managing acute care pathways and to payers monitoring costs of admissions classified under this DRG.
• Comparative effectiveness studies of invasive versus conservative early management strategies for high-risk angina patients: these trials compare outcomes of early invasive evaluation (e.g., coronary angiography with possible revascularization) versus optimized medical therapy and selective invasive follow-up for patients with unstable or crescendo angina. The population includes patients stratified by ischemic risk, comorbidities, and noninvasive testing results, and the research objective is to determine which approach reduces subsequent myocardial infarction, readmissions, and mortality. Findings impact decisions about utilization of diagnostic procedures, timing of interventions, and downstream costs—critical for hospitals coding under this DRG and for payers assessing value of early invasive care.
• Post-discharge secondary prevention and care-coordination trials focused on reducing readmissions and recurrent angina: these studies test interventions such as structured outpatient follow-up, medication adherence programs, cardiac rehabilitation referral uptake, and remote monitoring for patients discharged after an admission for angina. The patient cohort includes survivors of inpatient admissions for angina with varying adherence risks and comorbid conditions; the primary outcomes are readmission rates, recurrent angina episodes, functional status, and adherence to guideline-directed preventive therapies. This research is important to providers and payers because effective post-discharge programs can lower readmissions, improve long-term outcomes, and reduce total cost of care associated with this DRG.